PEGylated bilirubin nanoparticle as an anti-oxidative and anti-inflammatory demulcent in pancreatic islet xenotransplantation

Kim, Min Jun; Lee, Yonghyun; Jon, Sangyong; Lee, Dong Yun

doi:10.1016/j.biomaterials.2017.04.029

Cited by 84 publications

(68 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared to pristine bilirubin, BRNPs have more excellent water dispersibility, better pharmacokinetic properties, and higher accumulation in oxidative stress-induced inflammatory lesions. More importantly, BRNPs inherited the intrinsic powerful antioxidant capability of bilirubin, as evidenced by their efficacies in the treatment of a variety of oxidative stress-associated diseases, such as hepatic ischemia-reperfusion injury , asthma (Kim D. E. et al, 2017), IBD (Lee et al, 2016a), and pancreatic islet xenotransplantation (Kim M. J. et al, 2017). In addition, BRNPs protected different cells against cytotoxicity caused by H 2 O 2 and decreased inflammatory responses resulting from activated macrophages.…”

Section: Bilirubin-derived Nanoparticlesmentioning

confidence: 99%

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Chen

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Reactive oxygen species (ROS) are essential in regulating various physiological functions. However, overproduction of ROS is implicated in the pathogenesis of various inflammatory diseases. Antioxidant therapy has thus represented an effective strategy for the treatment of oxidative stress relevant inflammatory diseases. Conventional anti-oxidative agents showed limited in vivo effects owing to their non-specific distribution and low retention in disease sites. Over the past decades, significant achievements have been made in the development of antioxidant nanotherapies that exhibit multiple advantages such as excellent pharmacokinetics, stable anti-oxidative activity, and intrinsic ROS-scavenging properties. This review provides a comprehensive overview on recent advances in antioxidant nanotherapies, including ROS-scavenging inorganic nanoparticles, organic nanoparticles with intrinsic antioxidant activity, and drug-loaded anti-oxidant nanoparticles. We highlight the biomedical applications of antioxidant nanotherapies in the treatment of different inflammatory diseases, with an emphasis on inflammatory bowel disease, cardiovascular disease, and brain diseases. Current challenges and future perspectives to promote clinical translation of antioxidant nanotherapies are also briefly discussed.

show abstract

Section: Bilirubin-derived Nanoparticlesmentioning

confidence: 99%

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Chen

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…IRI manifests as an increase in inflammation and apoptosis that results in the dysfunction of hepatic cells, organ rejection, and ultimately liver failure. [60] Asthma is a chronic inflammatory airway disease. [56] The BRNPs we synthesized have potent antioxidant, anti-inflammatory, and anti-apoptotic properties, so we investigated their protective effects against IRI in mice.…”

Section: Bilirubinmentioning

confidence: 99%

“…A) Treatment with BRNPs has remarkable anti-inflammatory effects in a murine model of chemically induced colitis. [60] Copyright 2017, Elsevier Ltd. D) More efficient anti-inflammatory activity of BRNPs compared with UCB in a mouse model of asthma. [55] Copyright 2016, John Wiley and Sons.…”

Section: Perspective and Future Outlookmentioning

confidence: 99%

Naturally Occurring Bioactive Compound‐Derived Nanoparticles for Biomedical Applications

Saw

Lee

Jon

2019

Advanced Therapeutics

Self Cite

View full text Add to dashboard Cite

Bioactive, small molecular compounds from a variety of plants and organisms have tremendous potential for use as treatments for cancer, microbial infections, inflammatory diseases, and other medical conditions. There have also been attempts to use naturally occurring bioactive compounds as delivery carriers. Such bioactive, natural compound-derived nanocarriers are expected to have better biocompatibility than synthetic material-derived drug-delivery systems and also exhibit intrinsic therapeutic efficacy. Despite these expectations, however, research on the topic is limited and thus has been the subject of very few reviews. Here, the authors describe carriers derived from four typical naturally occurring bioactive compounds-curcumin, resveratrol, epigallocatechin gallate (EGCG) (an active ingredient in green tea), and bilirubin-that have been used for biomedical applications. In this review, the pros and cons of each bioactive small molecular compound and processes for synthesizing and preparing these compound-derived delivery carriers are discussed. A number of examples that show the potential of these delivery carriers as disease treatments are considered, and their future prospects for biomedical applications are assessed. Nanoparticles that simply encapsulate or encase such bioactive compounds are outside the scope of this review and thus are not considered.

show abstract

“…Hypoxia produces reactive oxygen species (ROS) in and around transplanted islets [78]. Because β cells contain low levels of antioxidative enzymes such as catalase, superoxide dismutase and glutathione peroxidase, they are prone to oxidative stress associated with ROS [79][80][81][82].…”

Section: Hypoxia Induced Inflammationmentioning

confidence: 99%

Regulation of Inflammatory Response in Islet Transplantation

Shindo¹,

Kanak²

2018

obm transplant

View full text Add to dashboard Cite

Islet cell transplantation is a developing treatment for patients suffering from severe Type-1 diabetes. The long-term insulin independence after islet cell transplantation has been difficult to achieve, and this has been linked to several factors. One of the major cause of poor long-term outcome is inflammation surrounding the islets. Inflammation in islets is caused at several stages, donor induced, during organ preservation, islet isolation stress, peri-transplant inflammation or instant blood mediated inflammatory reaction (IBMIR), and post-transplant hypoxia. In addition to inflammation, auto/allo-immune attack causes rejection and the toxicity of the immunosuppressive agents used can also affect islet transplant outcomes. In this review, we will summarize the various inflammatory processes that occur during islet transplantation along with past and previous approaches used to reduce inflammation in pre-clinical and clinical studies.

show abstract

PEGylated bilirubin nanoparticle as an anti-oxidative and anti-inflammatory demulcent in pancreatic islet xenotransplantation

Cited by 84 publications

References 54 publications

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Naturally Occurring Bioactive Compound‐Derived Nanoparticles for Biomedical Applications

Regulation of Inflammatory Response in Islet Transplantation

Contact Info

Product

Resources

About